Impaired thymopoiesis occurring during the thymic involution of tumor- bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and Al

被引:19
作者
Carrio, Roberto [1 ]
Lopez, Diana M. [1 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA
基金
美国国家卫生研究院;
关键词
tumor-bearing mice; thymic involution; apoptosis; Bcl-X-L; Al; T-CELL DEVELOPMENT; SURVIVAL-PROMOTING PROTEINS; MAMMARY-TUMOR; FAMILY-MEMBER; ACTIVATES APOPTOSIS; SEQUENCE SIMILARITY; IMMUNE-SYSTEM; DEATH; BCL-X(L); THYMOCYTES;
D O I
10.3892/ijmm_00000105
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
The thymus is a central lymphoid organ in which T lymphocytes undergo differentiation and maturation without the need for antigenic stimulation. Apoptosis (programmed cell death), plays a critical role in shaping the T cell repertoire, deleting unproductive as well as potentially autoreactive T cells. Thymic atrophy has been observed in several model systems, including aging, graft-vs-host-disease and tumor development. However, the mechanisms involved in this phenomenon remain to be completely elucidated. We have previously shown that the progressive growth of D1-DMBA-3 mammary tumor leads to extreme thymic atrophy in the host. This thymic involution is associated with an early block in T cell maturation at the triple negative stage of differentiation. In the present study we have used our murine mammary tumor model to further analyze the specific T cell subpopulations present in the thymus of tumor-bearing animals as well as to characterize the alterations of the apoptotic process present during the impaired thymopoiesis associated to this thymic involution. Flow cytometric analysis revealed a moderate increase in the percentages of single positive CD4(+) and CD8(+) cells within the CD3 negative population in the thymuses of tumor-bearing mice. Moreover, we observed a prolonged increase in apoptosis among thymocytes from tumor-bearing mice compared with thymocytes from normal mice during tumor development. Lastly, we found a major decrease of Bcl-X-L and Al, two crucial anti-apoptotic Bcl-2 family members that are developmentally regulated in T cells. Together, our data suggest that the severe thymic involution seen in mammary tumor bearers is due to an arrest in at least two steps of T cell differentiation and a down-regulation of important molecules that control programmed cell death.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 72 条
[1]
Early block in maturation is associated with thymic involution in mammary tumor-bearing mice [J].
Adkins, B ;
Charyulu, V ;
Sun, QL ;
Lobo, D ;
Lopez, DM .
JOURNAL OF IMMUNOLOGY, 2000, 164 (11) :5635-5640
[2]
Cellular interactions in thymocyte development [J].
Anderson, G ;
Moore, NC ;
Owen, JJT ;
Jenkinson, EJ .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :73-99
[3]
Thymic involution in aging [J].
Aspinall, R ;
Andrew, D .
JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (04) :250-256
[4]
T cell development, ageing and interleukin-7 [J].
Aspinall, Richard .
MECHANISMS OF AGEING AND DEVELOPMENT, 2006, 127 (06) :572-578
[5]
CREB function is required for normal thymic cellularity and post-irradiation recovery [J].
Baumann, S ;
Kyewski, B ;
Bleckmann, SC ;
Greiner, E ;
Rudolph, D ;
Schmid, W ;
Ramsay, RG ;
Krammer, PH ;
Schütz, G ;
Mantamadiotis, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (07) :1961-1971
[6]
Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671
[7]
CD28 COSTIMULATION CAN PROMOTE T-CELL SURVIVAL BY ENHANCING THE EXPRESSION OF BCL-X(L) [J].
BOISE, LH ;
MINN, AJ ;
NOEL, PJ ;
JUNE, CH ;
ACCAVITTI, MA ;
LINDSTEN, T ;
THOMPSON, CB .
IMMUNITY, 1995, 3 (01) :87-98
[8]
BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[9]
On the brink of becoming a T cell [J].
Borowski, C ;
Martin, C ;
Gounari, F ;
Haughn, L ;
Aifantis, L ;
Grassi, F ;
Boehmer, HY .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (02) :200-206
[10]
BOYD JM, 1995, ONCOGENE, V11, P1921